EA200001199A1 - Терапевтические комбинации, содержащие селективный модулятор рецептора эстрогена и паратироидный гормон - Google Patents

Терапевтические комбинации, содержащие селективный модулятор рецептора эстрогена и паратироидный гормон

Info

Publication number
EA200001199A1
EA200001199A1 EA200001199A EA200001199A EA200001199A1 EA 200001199 A1 EA200001199 A1 EA 200001199A1 EA 200001199 A EA200001199 A EA 200001199A EA 200001199 A EA200001199 A EA 200001199A EA 200001199 A1 EA200001199 A1 EA 200001199A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
estrogen receptor
receptor modulator
selective estrogen
therapeutic combinations
Prior art date
Application number
EA200001199A
Other languages
English (en)
Inventor
Хуа Зу Ке
Дэвид Дуан Томпсон
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200001199A1 publication Critical patent/EA200001199A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

Настоящее изобретение направлено на создание фармацевтической комбинации композиции и способов, включающих (-)-цис-6-фенил-5-(4-(2-пирролидин-1-ил-этокси)-фенил)-5,6,7,8-тетрагидронафталин-2-ол или его фармацевтически приемлемую соль, паратироидный гормон или его биологически активный фрагмент, способы использования таких композиций и наборов, содержащих такие композиции. Эти композиции полезны для лечения мышечно-скелетной хрупкости, включая остеопороз, остеопорозный перелом, потерю костной массы и хрупкость.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001199A 1998-06-16 1999-05-26 Терапевтические комбинации, содержащие селективный модулятор рецептора эстрогена и паратироидный гормон EA200001199A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8947998P 1998-06-16 1998-06-16
PCT/IB1999/000949 WO1999065482A1 (en) 1998-06-16 1999-05-26 Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone

Publications (1)

Publication Number Publication Date
EA200001199A1 true EA200001199A1 (ru) 2001-04-23

Family

ID=22217879

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001199A EA200001199A1 (ru) 1998-06-16 1999-05-26 Терапевтические комбинации, содержащие селективный модулятор рецептора эстрогена и паратироидный гормон

Country Status (34)

Country Link
US (1) US6132774A (ru)
EP (1) EP1094808A1 (ru)
JP (1) JP2002518323A (ru)
KR (1) KR20010052818A (ru)
CN (1) CN1305373A (ru)
AP (1) AP9901580A0 (ru)
AR (1) AR018867A1 (ru)
AU (1) AU3725999A (ru)
BG (1) BG105125A (ru)
BR (1) BR9911228A (ru)
CA (1) CA2335078A1 (ru)
CO (1) CO5070584A1 (ru)
EA (1) EA200001199A1 (ru)
GT (1) GT199900066A (ru)
HN (1) HN1999000063A (ru)
HR (1) HRP20000858A2 (ru)
HU (1) HUP0102759A3 (ru)
ID (1) ID26873A (ru)
IL (1) IL139588A0 (ru)
IS (1) IS5719A (ru)
MA (1) MA26649A1 (ru)
NO (1) NO20006313L (ru)
NZ (1) NZ508039A (ru)
OA (1) OA11566A (ru)
PA (1) PA8471201A1 (ru)
PE (1) PE20000644A1 (ru)
PL (1) PL344982A1 (ru)
SK (1) SK18922000A3 (ru)
TN (1) TNSN99119A1 (ru)
TR (1) TR200003567T2 (ru)
UA (1) UA60367C2 (ru)
WO (1) WO1999065482A1 (ru)
YU (1) YU75800A (ru)
ZA (1) ZA993972B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20030191096A1 (en) * 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
CN111067907A (zh) * 2018-10-18 2020-04-28 常州大学 孕激素在抑制血管内皮生长因子表达中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
KR20010052818A (ko) 2001-06-25
CO5070584A1 (es) 2001-08-28
PL344982A1 (en) 2001-11-19
NO20006313D0 (no) 2000-12-12
BR9911228A (pt) 2001-02-13
NZ508039A (en) 2003-03-28
US6132774A (en) 2000-10-17
AU3725999A (en) 2000-01-05
ZA993972B (en) 2000-12-15
IS5719A (is) 2000-11-21
CA2335078A1 (en) 1999-12-23
AP9901580A0 (en) 1999-06-30
BG105125A (en) 2001-11-30
HUP0102759A2 (hu) 2002-03-28
HN1999000063A (es) 2000-01-12
WO1999065482A1 (en) 1999-12-23
IL139588A0 (en) 2002-02-10
UA60367C2 (ru) 2003-10-15
TR200003567T2 (tr) 2001-06-21
NO20006313L (no) 2000-12-12
HRP20000858A2 (en) 2001-10-31
EP1094808A1 (en) 2001-05-02
OA11566A (en) 2004-05-26
MA26649A1 (fr) 2004-12-20
CN1305373A (zh) 2001-07-25
GT199900066A (es) 2000-10-31
PA8471201A1 (es) 2000-09-29
AR018867A1 (es) 2001-12-12
PE20000644A1 (es) 2000-08-02
YU75800A (sh) 2003-12-31
ID26873A (id) 2001-02-15
JP2002518323A (ja) 2002-06-25
TNSN99119A1 (fr) 2005-11-10
HUP0102759A3 (en) 2002-12-28
SK18922000A3 (sk) 2001-09-11

Similar Documents

Publication Publication Date Title
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
YU7797A (sh) Kombinovana terapija za osteoporozu
EA200001199A1 (ru) Терапевтические комбинации, содержащие селективный модулятор рецептора эстрогена и паратироидный гормон
EP0911321A3 (en) Compounds for the treatment of osteoporosis
ATE180479T1 (de) Sulfonat- und carbamatderivate von 3-aroyl- benzo(beta)thiophenen
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
MXPA04000757A (es) Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
AP9801269A0 (en) Prostaglandin agonists.
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
DE60233803D1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
ES2101334T3 (es) Utilizacion terapeutica de la fosforil-l-serina-n-acil-esfingosina.
EA200001186A1 (ru) Терапевтические комбинации (избирательных) модуляторов рецепторов эстрогенов (имрэ) и стимуляторов секреции гормона роста (ссгр) для лечения скелетно-мышечной слабости
PT966968E (pt) Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2
DE60028682D1 (de) Wachstumhormone Inhibitoren Enthaltende pharmazeutische Zubereitungen oder ihre biologisch aktive Fragmente zur Behandlung von uterinen Myomas
ECSP993016A (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratoroidea